Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding

Thrombosis Journal - 2006
Philipp Eller1, Christoph Pechlaner1, Wiedermann Cj2
1Division of General Internal Medicine, Department of Medicine, Medical University of Innsbruck, Innsbruck, Austria
22nd Division of Internal Medicine, Department of Medicine, Central Hospital of Bolzano, Bolzano, Italy

Tóm tắt

Abstract Background For patients with a normal coagulation system, who experience serious bleeding, sound evidence for recombinant activated factor VII (rFVIIa) as an effective haemostatic agent is only scarcely available so far from controlled clinical trials. In systematic reviews on the clinical use of rFVIIa, treatment failures were only rarely reported. Case presentation We present a 45-year old, Caucasian male with persistent intestinal bleeding due to enterocolitis associated with cytomegalovirus infection and acute graft-versus-host-disease. He had received allogeneic peripheral blood stem cell transplantation from an unrelated HLA-identical donor because of chronic myelogenous leukaemia diagnosed two years earlier. Bleeding started at day 18 after transplantation with bloody diarrhea, which was treated with multiple transfusions of fresh frozen plasma, platelet, and red blood cell concentrates, and continued relentlessly, despite all efforts, including continued transfusions, high-dose prednisolone, broad antibiotic and antiviral coverage, and tranexamic acid. Recombinant FVIIa was started at boluses of 90–120 μg/kg every 4–8 hours. Despite more than 10 doses, recurrent severe bleeding progressed to refractory shock, multiorgan failure and death. Conclusions Little can be concluded from single case reports of clinical improvement, because publication bias in favour of positive effects is likely. Our case suggests that rFVIIa is not a panacea, in particular for severe bleeding after bone-marrow transplantation. As long as rigorous, controlled studies or comprehensive registries are lacking, conventional interventions remain the standard of care in non-haemophilic patients with severe bleeding.

Từ khóa


Tài liệu tham khảo

Parameswaran R, Shapiro AD, Gill JC, Kessler CM: Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005, 11(2):100-106. 10.1111/j.1365-2516.2005.01075.x

Siddiqui MA, Scott LJ: Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs 2005, 65(8):1161-1177. 10.2165/00003495-200565080-00008

Levi M, Peters M, Buller HR: Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005, 33(4):883-890. 10.1097/01.CCM.0000159087.85970.38

Mayer SA, Brun NC, Begtrup K, et al.: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352(8):777-785. 10.1056/NEJMoa042991

Pavese P, Bonadona A, Beaubien J, et al.: FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anaesth 2005, 52(1):26-29.

Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004, 104(13):3858-3864. 10.1182/blood-2004-06-2223

Lam MS, Sims-McCallum RP: Recombinant factor VIIa in the treatment of non-hemophiliac bleeding. Ann Pharmacother 2005, 39(5):885-891. 10.1345/aph.1E553

Clark AD, Gordon WC, Walker ID, Tait RC: 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004, 86(2):120-124. 10.1111/j.0042-9007.2004.00393.x

Lodge JP, Jonas S, Oussoultzoglou E, et al.: Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005, 102(2):269-275. 10.1097/00000542-200502000-00006

Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM: Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 2005, 94(5):586-591. 10.1093/bja/aei102

Bosch J, Thabut D, Bendtsen F, et al.: Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004, 127(4):1123-1130. 10.1053/j.gastro.2004.07.015

Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D: Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant 2001, 28(4):405-407. 10.1038/sj.bmt.1703157

Hicks K, Peng D, Gajewski JL: Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002, 30(12):975-978. 10.1038/sj.bmt.1703731

Karimi M, Zakerinia M, Khojasteh HN, Ramzi M, Ahmad E: Successful treatment of cyclophosphamide induced intractable hemorrhagic cystitis with recombinant FVIIa (NovoSeven) after allogenic bone marrow transplantation. J Thromb Haemost 2004, 2(10):1853-1855. 10.1111/j.1538-7836.2004.00917.x

Pihusch M, Bacigalupo A, Szer J, et al.: Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005, 3(9):1935-1944. 10.1111/j.1538-7836.2005.01523.x

Thông tin
Thông tin xuất bản

Thrombosis Journal

Thông tin tác giả